PineTree Therapeutics is developing the AbReptor and TAER-TAB platforms, which utilize bispecific and multi-specific antibodies to target and degrade membrane-bound and extracellular proteins in cancer cells. These therapies aim to address the unmet medical needs in oncology by effectively targeting difficult-to-reach receptors across various cancer types.
Funding
$50.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIFounders
Product
Problem
Many cancers express difficult-to-target receptors, limiting the effectiveness of existing therapies and leaving significant unmet needs in oncology. Traditional antibody therapies often struggle to reach and degrade these membrane-bound and extracellular proteins effectively across various cancer types.
Solution
PineTree Therapeutics is developing two novel platforms, AbReptor and TAER-TAB, that utilize bispecific and multi-specific antibodies to target and degrade these challenging proteins. The AbReptor platform is a modular antibody platform designed for degrading membrane-bound and extracellular proteins. The TAER-TAB technology is a bispecific antibody platform targeting a unique receptor present on cancer cells in lung, breast, pancreatic, cervical, colon, kidney, ovarian, and stomach cancers. These platforms aim to create targeted biologic therapeutics for unmet needs in oncology.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more effective therapies for cancers with difficult-to-target receptors.
Features
- AbReptor: A modular bi-specific and multi-specific antibody platform designed to degrade membrane-bound and extracellular proteins.
- TAER-TAB: A bispecific antibody platform targeting a unique receptor present on cancer cells in multiple cancer types.
- Designed to target difficult-to-reach receptors on cancer cells.